Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ruth Matthews
Institution:
Institute of Cancer Research
Observed institutions:
Institute of Cancer Research,
Royal Marsden Hospital
ORCID:
0000-0003-1697-3109
Observed ORCID:
0000-0003-1697-3109
OpenAlex ID:
A5062911596
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance
2023
·
Christina Guo
, Adam Sharp
, et al.
·
Nature
·
160
PDF
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2 - and Non– BRCA1/2 -Mutant Cancers
2020
·
Timothy A. Yap
, Rebecca Kristeleit
, et al.
·
Cancer Discovery
·
146
A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC).
2023
·
Christina Guo
, Simon J. Crabb
, et al.
·
Journal of Clinical Oncology
·
4
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer
2026
·
Khobe Chandran
, Christina Guo
, et al.
·
Investigational New Drugs
·
2
PDF
Supplementary Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers
2023
·
Timothy A. Yap
, Rebecca Kristeleit
, et al.
Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers
2023
·
Timothy A. Yap
, Rebecca Kristeleit
, et al.
Show more works
View as search
Works count:
6
Citation count:
312
H-index:
3
I10-index:
2
Year
Topic
Type